公开(公告)号：US20220262458A1

公开(公告)日：2022-08-18

申请号：US17629327

申请日：2020-07-24

Applicant: Genentech, Inc.

Inventor： Yasin SENBABAOGLU ,  Christine Carine MOUSSION

IPC: G16B20/00 ,  G16B40/30

Abstract: Embodiments disclosed herein generally relate to classifying a tumor, based on gene expression data, as being neurally related or non-neurally related. The tumor may be classified using a machine-learning model, which may have been trained to differentiate gene-expression data associated with neuronal or neuroendocrine tumors from gene-expression data associated with non-neuronal and non-neuroendocrine tumors. Differential treatment and/or treatment recommendations may be provided based on the classification. First-line checkpoint blockade therapy may be used or recommended when a tumor is identified as being non-neurally related, and a combination therapy (e.g., initial chemotherapy and subsequent checkpoint blockade therapy) may be used or recommended when a tumor is identified as being neurally related.

公开(公告)号：US20200263261A1

公开(公告)日：2020-08-20

申请号：US16867125

申请日：2020-05-05

Applicant: Genentech, Inc.

Inventor： Yinghui GUAN ,  Yasin SENBABAOGLU ,  Shannon TURLEY ,  Yulei WANG

IPC: C12Q1/6886 ,  G01N33/574 ,  A61K39/395

Abstract: The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer (e.g., a bladder cancer (e.g., UC, e.g., mUC), a kidney cancer, a lung cancer, a liver cancer, an ovarian cancer, a pancreatic cancer, a colorectal cancer, or a breast cancer). The invention is based, at least in part, on the discovery that expression levels of one or more biomarkers described herein in a sample from an individual having cancer can be used in methods of identifying an individual having a cancer who may benefit with an anti-cancer therapy that includes an immunotherapy (e.g., a PD-L1 axis binding antagonist such as an anti-PD-L1 antibody (e.g., atezolizumab)) and a suppressive stromal antagonist (e.g., a TGF-β antagonist), methods for selecting a therapy for an individual having cancer, methods of treating an individual having cancer, methods for assessing a response or monitoring the response of an individual to treatment with an anti-cancer therapy that includes an immunotherapy (e.g., a PD-L1 axis binding antagonist such as an anti-PD-L1 antibody (e.g., atezolizumab)) and a suppressive stromal antagonist (e.g., a TGF-β antagonist), and related kits, anti-cancer therapies, and uses.

公开(公告)号：US20240011098A1

公开(公告)日：2024-01-11

申请号：US17901481

申请日：2022-09-01

Applicant: Genentech, Inc.

Inventor： Yinghui GUAN ,  Yasin SENBABAOGLU ,  Shannon TURLEY ,  Yulei WANG

IPC: C12Q1/6886 ,  A61K39/395 ,  G01N33/574

CPC classification number: C12Q1/6886 ,  A61K39/39558 ,  G01N33/57488 ,  C12Q2600/106 ,  C12Q2600/158

Abstract: The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer (e.g., a bladder cancer (e.g., UC, e.g., mUC), a kidney cancer, a lung cancer, a liver cancer, an ovarian cancer, a pancreatic cancer, a colorectal cancer, or a breast cancer). The invention is based, at least in part, on the discovery that expression levels of one or more biomarkers described herein in a sample from an individual having cancer can be used in methods of identifying an individual having a cancer who may benefit with an anti-cancer therapy that includes an immunotherapy (e.g., a PD-L1 axis binding antagonist such as an anti-PD-L1 antibody (e.g., atezolizumab)) and a suppressive stromal antagonist (e.g., a TGF-β antagonist), methods for selecting a therapy for an individual having cancer, methods of treating an individual having cancer, methods for assessing a response or monitoring the response of an individual to treatment with an anti-cancer therapy that includes an immunotherapy (e.g., a PD-L1 axis binding antagonist such as an anti-PD-L1 antibody (e.g., atezolizumab)) and a suppressive stromal antagonist (e.g., a TGF-β antagonist), and related kits, anti-cancer therapies, and uses.